CR or mCR in 86% of patients within the first 12 months - Venetoclax-resistant secondary AML transformed from CMML responds to lenzilumab BURLINGAME, CA / ACCESS Newswire / November 4, 2025 / Taran ...

We often applaud animals for learning tricks. But until recently, we rarely acknowledged that significant intelligence ...

So begins the second verse of the hymn ‘I vow to thee my country.’ ...

CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, ...

Q3 2025 Earnings Call Transcript November 3, 2025 Karyopharm Therapeutics Inc. misses on earnings expectations. Reported EPS ...

Calliditas Therapeutics (Calliditas), an Asahi Kasei company, announced today that new data will be presented at the 2025 American Society of Nephrology Kidney Week, taking place from November 6 to 9 ...

For his second act with Hublot, Daniel Arsham transforms time into art once more, unveiling a new wearable in Singapore ...

Q3 2025 Earnings Call Transcript November 4, 2025 CeriBell, Inc. beats earnings expectations. Reported EPS is $-0.37, expectations were $-0.43. Operator: Good afternoon, and thank you all for ...

Paws for a Cause The Peter Zippi Memorial Fund (PZF) invites the community to its annual Open House and Fundraiser on Sunday, November 9, 11 ...

ITAT Mumbai held that delay in filing Form 10B does not invalidate a trust’s exemption claim if the form is submitted before assessment completion and the error is ...

So begins the second verse of the hymn ‘I vow to thee my country.’ ...